AU2006260599A1 - Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract - Google Patents

Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract Download PDF

Info

Publication number
AU2006260599A1
AU2006260599A1 AU2006260599A AU2006260599A AU2006260599A1 AU 2006260599 A1 AU2006260599 A1 AU 2006260599A1 AU 2006260599 A AU2006260599 A AU 2006260599A AU 2006260599 A AU2006260599 A AU 2006260599A AU 2006260599 A1 AU2006260599 A1 AU 2006260599A1
Authority
AU
Australia
Prior art keywords
tissue factor
pathway inhibitor
factor pathway
tfpi
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006260599A
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drugrecure AS
Original Assignee
Drugrecure AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure AS filed Critical Drugrecure AS
Publication of AU2006260599A1 publication Critical patent/AU2006260599A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2006260599A 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract Abandoned AU2006260599A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
US60/693,968 2005-06-24
PCT/IB2006/002602 WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

Publications (1)

Publication Number Publication Date
AU2006260599A1 true AU2006260599A1 (en) 2006-12-28

Family

ID=37570814

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006260599A Abandoned AU2006260599A1 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
AU2006273696A Ceased AU2006273696B2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006273696A Ceased AU2006273696B2 (en) 2005-06-24 2006-06-23 Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract

Country Status (14)

Country Link
US (3) US20100279925A1 (https=)
EP (3) EP1896059B1 (https=)
JP (3) JP2008543926A (https=)
KR (2) KR20080074085A (https=)
CN (2) CN101262880A (https=)
AU (2) AU2006260599A1 (https=)
BR (2) BRPI0611710A2 (https=)
CA (2) CA2612597C (https=)
DK (3) DK1898945T3 (https=)
IL (2) IL188220A0 (https=)
NO (2) NO20080434L (https=)
RU (2) RU2496515C2 (https=)
WO (3) WO2007012976A2 (https=)
ZA (2) ZA200800251B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101787B1 (en) * 2006-12-11 2013-09-18 Drugrecure ApS Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
AU2013286812B2 (en) 2012-07-04 2017-04-20 Zz Biotech Llc Treatment of inflammatory skin disorders
PT3137102T (pt) * 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
PL3131572T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Analog apc do zastosowania w zaleczaniu rany
WO2018053029A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
EP0946715B1 (en) * 1996-11-08 2006-03-29 Oklahoma Medical Research Foundation Use of a modified protein c
WO1998032459A1 (en) * 1997-01-29 1998-07-30 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
WO2001057193A2 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002338487A1 (en) * 2001-05-02 2002-11-11 Novo Nordisk A/S Modified fvii in treatment of ards
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EP1446140A4 (en) * 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
KR100674315B1 (ko) * 2002-02-08 2007-01-24 에스케이 주식회사 가열로 튜브 세척제 및 세척방법
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
DK1791555T3 (da) * 2004-09-10 2013-06-10 Pharmaorigin Aps Fremgangsmåde til behandling af lokal tracheal, bronchial eller alveolær blødning eller hæmoptyse
US8563511B2 (en) 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
DK1906994T3 (da) 2014-07-21
WO2006136963A3 (en) 2007-07-12
DK1896059T3 (da) 2013-04-08
ZA200800251B (en) 2009-04-29
EP1898945B1 (en) 2012-12-19
CA2612646C (en) 2015-11-24
IL188221A0 (en) 2008-03-20
WO2007012976A3 (en) 2007-07-12
JP2008543925A (ja) 2008-12-04
AU2006273696B2 (en) 2012-08-30
KR20080071116A (ko) 2008-08-01
HK1114567A1 (en) 2008-11-07
BRPI0611710A2 (pt) 2011-12-20
IL188220A0 (en) 2008-03-20
NO20080434L (no) 2008-03-17
JP2008543926A (ja) 2008-12-04
BRPI0613137A2 (pt) 2010-12-21
NO20080433L (no) 2008-03-19
RU2496515C2 (ru) 2013-10-27
JP2013151510A (ja) 2013-08-08
RU2008102656A (ru) 2009-07-27
ZA200800255B (en) 2009-04-29
RU2008102655A (ru) 2009-07-27
US20100279925A1 (en) 2010-11-04
US20100160218A1 (en) 2010-06-24
US8088728B2 (en) 2012-01-03
AU2006273696A1 (en) 2007-02-01
EP1898945A2 (en) 2008-03-19
WO2007012976A2 (en) 2007-02-01
WO2006136962A3 (en) 2007-07-12
CA2612646A1 (en) 2006-12-28
EP1906994A2 (en) 2008-04-09
EP1896059B1 (en) 2012-12-19
RU2496516C2 (ru) 2013-10-27
EP1906994B1 (en) 2014-04-23
CN101262879A (zh) 2008-09-10
EP1896059A2 (en) 2008-03-12
CA2612597A1 (en) 2007-02-01
CN101262879B (zh) 2013-04-10
US20100297099A1 (en) 2010-11-25
DK1898945T3 (da) 2013-03-25
CN101262880A (zh) 2008-09-10
WO2006136963A2 (en) 2006-12-28
KR20080074085A (ko) 2008-08-12
WO2006136962A2 (en) 2006-12-28
CA2612597C (en) 2015-03-31

Similar Documents

Publication Publication Date Title
JP6001151B2 (ja) 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
JP2013151510A (ja) 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与
US20150174204A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
HK1114567B (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
MX2007016370A (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio
HK1135911B (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor
HK1135911A (en) Enhancing pulmonary host defense via administration of granulocyte-macrophage colony stimulating factor

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period